SEHK:1541Biotechs
ImmuneOnco Biopharmaceuticals (SEHK:1541) Losses Narrow 23.6% Annually Challenging Bearish Narratives
ImmuneOnco Biopharmaceuticals (Shanghai) (SEHK:1541) has laid out its FY 2025 scorecard with first half revenue of C¥44.0 million and a basic EPS loss of C¥0.37, alongside net income loss excluding extra items of C¥152.6 million. The company has reported revenue of C¥0.7 million in 1H 2024, C¥78.8 million in 2H 2024 and C¥44.0 million in 1H 2025. Over the same periods, basic EPS losses were C¥0.44, C¥0.39 and C¥0.37 respectively, providing a basis to assess how effectively revenue is being...